156 related articles for article (PubMed ID: 33048270)
1. Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate.
Zhang L; Zhang D; Gao M; Jin Q; Jiang C; Wu T; Feng Y; Ni Y; Yin Z; Zhang J
Mol Imaging Biol; 2021 Apr; 23(2):220-229. PubMed ID: 33048270
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Diindole-Based MRI Contrast Agent for In Vivo Visualization of Necrosis.
Zhang L; Liu L; Zhang D; Jin Q; Gao M; Wu T; Feng Y; Ni Y; Yin Z; Zhang J
Mol Imaging Biol; 2020 Jun; 22(3):593-601. PubMed ID: 31332630
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis.
Zhang A; Wu T; Bian L; Li P; Liu Q; Zhang D; Jin Q; Zhang J; Huang G; Song S
Mol Imaging Biol; 2020 Jun; 22(3):515-525. PubMed ID: 31250330
[TBL] [Abstract][Full Text] [Related]
4. SPECT Imaging of Treatment-Related Tumor Necrosis Using Technetium-99m-Labeled Rhein.
Liang J; Luo Q; Zhang D; Jin Q; Liu L; Liu W; Gao M; Zhang J; Yin Z
Mol Imaging Biol; 2019 Aug; 21(4):660-668. PubMed ID: 30338432
[TBL] [Abstract][Full Text] [Related]
5. Rhein-based necrosis-avid MRI contrast agents for early evaluation of tumor response to microwave ablation therapy.
Wu T; Zhang J; Jin Q; Gao M; Zhang D; Zhang L; Feng Y; Ni Y; Yin Z
Magn Reson Med; 2019 Dec; 82(6):2212-2224. PubMed ID: 31418484
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Evaluation of Rhein-Based MRI Contrast Agents for in Vivo Visualization of Necrosis.
Bian L; Gao M; Zhang D; Ji A; Su C; Duan X; Luo Q; Huang D; Feng Y; Ni Y; Yin Z; Jin Q; Zhang J
Anal Chem; 2018 Nov; 90(22):13249-13256. PubMed ID: 30379067
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
8. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
9. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
10. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
12. Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
Gao M; Yao N; Huang D; Jiang C; Feng Y; Li Y; Lou B; Peng F; Sun Z; Ni Y; Zhang J
J Drug Target; 2015 Jun; 23(5):436-43. PubMed ID: 25582132
[TBL] [Abstract][Full Text] [Related]
13. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled Rhein as Small-Molecule Necrosis Avid Agents for Imaging of Necrotic Myocardium.
Luo Q; Jin Q; Su C; Zhang D; Jiang C; Fish AF; Feng Y; Ni Y; Zhang J; Yin Z
Anal Chem; 2017 Jan; 89(2):1260-1266. PubMed ID: 27981843
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.
Zhang D; Gao M; Yao N; Jiang C; Liu W; Li T; Song S; Huang D; Yin Z; Qiu Y; Jin Q
Contrast Media Mol Imaging; 2018; 2018():5237950. PubMed ID: 29681781
[TBL] [Abstract][Full Text] [Related]
18. First Evaluation of Radioiodinated Flavonoids as Necrosis-Avid Agents and Application in Early Assessment of Tumor Necrosis.
Liang J; Sun Z; Zhang D; Jin Q; Cai L; Ma L; Liu W; Ni Y; Zhang J; Yin Z
Mol Pharm; 2018 Jan; 15(1):207-215. PubMed ID: 29226682
[TBL] [Abstract][Full Text] [Related]
19. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions.
Sun X; Wang H; Chen F; De Keyzer F; Yu J; Jiang Y; Feng Y; Li J; Marchal G; Ni Y
J Magn Reson Imaging; 2009 Mar; 29(3):621-8. PubMed ID: 19243058
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
